AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03355274 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires of Quality of Life (QoL)
Description: Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.
Study NCT01314872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.
Study NCT01686672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Intervention
Description: Behavioral
Study NCT03522012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
Study NCT03522012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Day 1 of Cohort 1
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 + digoxin
Description: Day 19 of Cohort 1
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Day 1 of Cohort 2
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin + BCX7353
Description: Day 15 of Cohort 1
Study NCT03136237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine + BCX7353
Description: Day 14 of Cohort 3
Study NCT04620837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
Study NCT04620837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
Study NCT03803007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ACT017 1000 mg
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study NCT03803007 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF Placebo
Description: Placebo only, oral administration
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACEi
Description: Administer same as pre-treatment regimen.
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi
Description: Administer same as pre-treatment regimen.
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOS
Description: Administer same as pre-treatment regimen
Study NCT00318474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOS
Description: Administer same as pre-treatment regimen
Study NCT01297517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study NCT01297517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%
Study NCT01297517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study NCT02484846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
Study NCT02484846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in bed
Description: Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
Study NCT02462772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabotegravir
Description: Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
Study NCT02462772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
Study NCT01996241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level, structural and norms-based intervention
Description: Receive multi-level, structural and norms-based intervention
Study NCT03155464 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Order of two elements of surgical procedure
Description: Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
Study NCT03155464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
Study NCT00302380 — intervention group
Intervention type: RADIATION
Intervention: PET imaging using C-11 altropane as the ligand.
Description: A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
Study NCT02752113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin and Linagliptin
Description: Empagliflozin and Linagliptin
Study NCT02752113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Insulin sc
Description: Metformin and Insulin sc
Study NCT00092118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: one 10 mg tablet, taken once daily at bed time for 6 weeks
Study NCT00092118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: one placebo tablet, taken once daily at bed time for 6 weeks
Study NCT00090025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
Study NCT00090025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil Plus Leucovorin
Description: 5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
Study NCT02393794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum compound
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Ertugliflozin 5 mg
Description: Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Ertugliflozin 10 mg
Description: Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Ertugliflozin 10 mg
Description: Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to sitagliptin 100 mg
Description: Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin >= 1500 mg/day
Description: Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin >= 1500 mg/day
Description: Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
Study NCT02099110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
Study NCT02099110 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
Study NCT02099110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
Study NCT02680808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam with F901318
Description: Pharmacokinetics of midazolam with F901318
Study NCT02110303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: oral, 90mg tablets, twice daily, 12 month duration
Study NCT02110303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical to ticagrelor), twice daily, 12 month duration
Study NCT00488644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 75 mcg by mouth (PO) Daily for 8 Weeks
Study NCT00488644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: 15 mcg PO Daily for 8 Weeks
Study NCT02547792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-BYW.10 (Low Dose) Oral Vaccine
Description: Enteric coated tablet for oral delivery
Study NCT02547792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-BYW.10 (High Dose) Oral Vaccine
Description: Enteric coated tablet for oral delivery
Study NCT02547792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Enteric coated tablet for oral delivery
Study NCT03142009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergenerational culturally adapted curriculum
Description: Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week.
Study NCT06325735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: None intervention
Description: None intervention, observational study
Study NCT05027659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
Study NCT02017158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Sprouts
Description: The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
Study NCT01994941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients.
Study NCT01994941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients.
Study NCT01994941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used.
Study NCT04509336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Description: 100 mg twice daily
Study NCT04509336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
Study NCT01921101 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intensive medical nutrition
Description: provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
Study NCT01921101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: participants will receive standard care for nutrition received from hospital admission to discharge
Study NCT02508350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
Study NCT02508350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: determination of plasma concentration
Description: A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
Study NCT03857529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation and electrical stimulator
Description: Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration.